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Abstract
The adhesin NadA favors cell adhesion/invasion by hypervirulent Neisseria meningitidis B (MenB). Its recombinant form
NadAD351–405, devoid of the outer membrane domain, is an immunogenic candidate for an anti-MenB vaccine able to
stimulate monocytes, macrophages and dendritic cells. In this study we investigated the molecular mechanism of
NadAD351–405 cellular effects in monocytes. We show that NadAD351–405 (against which we obtained polyclonal antibodies in
rabbits), binds to hsp90, but not to other extracellular homologous heat shock proteins grp94 and hsp70, in vitro and on the
surface of monocytes, in a temperature dependent way. Pre-incubation of monocytes with the MenB soluble adhesin
interfered with the binding of anti-hsp90 and anti-hsp70 antibodies to hsp90 and hsp70 at 37uC, a condition in which
specific cell-binding occurs, but not at 0uC, a condition in which specific cell-binding is very diminished. Conversely, pre-
incubation of monocytes with anti-hsp90 and anti-hsp70 antibodies did not affected NadAD351–405 cell binding in any
temperature condition, indicating that it associates to another receptor on their plasma membrane and then laterally
diffuses to encounter hsp90. Consistently, polymixin B interfered with NadAD351–405 /hsp90 association, abrogated the
decrease of anti-hsp90 antibodies binding to the cell surface due to NadAD351–405 and inhibited adhesin-induced cytokine/
chemokine secretion without affecting monocyte-adhesin binding. Co-stimulation of monocytes with anti-hsp90 antibodies
and NadAD351–405 determined a stronger but polymixin B insensitive cell activation. This indicated that the formation of a
recombinant NadA/hsp90/hsp70 complex, although essential for full monocyte stimulation, can be replaced by anti-hsp90
antibody/hsp90 binding. Finally, the activation of monocytes by NadAD351–405 alone or in the presence of anti-hsp90
antibodies were both inhibited by neutralizing anti-TLR4 antibodies, but not by anti-TLR2 antibodies. We propose that
hsp90-dependent recruitment into an hsp90/hsp70/TLR4 transducing signal complex is necessary for the immune-
stimulating activity of NadAD351–405 anti-MenB vaccine candidate.
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Introduction
Neisseria meningitidis is a principal cause of sudden death for
septic shock and meningitidis [1], [2]. Hypervirulent meningo-
coccal B serotypes, mostly responsible for infections occurring in
developed countries, often express the Oligomeric Coiled-coil
Adhesin (OCA) NadA (Neisseria meningitidis Adhesin A) [3], [4].
NadA predicted structure comprises a COOH terminal domain
necessary for anchorage to the outer membrane, an intermediate
stalk rich in a helices, with a leucine zipper, and a NH2 terminal
globular region containing the binding site(s) for a still unknown
NadA cellular receptor [5]. The 45 KDa NadA polypeptide
assembles in trimers expected to form a super-molecular array on
the bacterial surface, similarly to other homologous OCA
adhesins [6]. A soluble recombinant deletion mutant of NadA
(NadAD351–405), retaining a native-oligomeric conformation, has
been shown to be an effective immunogen in animal models,
inducing bactericidal antibodies. Therefore NadAD351–405 is at
present one of the component of a multivalent anti-Men B
vaccine under development [7]. Expression of NadA on E. coli
determines an increase bacterial adhesion to and invasion of
conjunctival cells, while its presence on N. meningitidis seems to
increase epithelial cell invasion prevalently [5].
In addition it has also been observed that human monocytes,
macrophages and dendritic cells differentiated in vitro from
monocytes all express specific binding sites for NadAD351–405 and
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NadAD351–405 not only is intrinsically immunogenic, but is
expected to increase antigen presentation as a specific adjuvant
interacting with cell surface receptors. The presence of appropriate
co-stimuli, in particular IFNc or the TLR7 agonist R848,
optimizes the cellular effects of soluble NadA. Interestingly, the
membrane organization of full length NadA in MenB outer
membranes vesicles (OMVs) increases their intrinsic efficacy in
stimulating human macrophages antigen presentation machinery
but not the induction of shock-related cytokines in circulating
monocytes, independently on IFNc [10], suggesting that pro-
immune action of wt NadA might play a role also in vivo.
Because of its importance as an anti-MenB vaccine candidate,
in this study we engaged in the characterization of the molecular
mechanism underlying the activation of myeloid cells by
NadAD351–405. To address this issue, we decided to search for
proteins able to bind to the recombinant adhesin present in total
lysates from human monocytes, a primary cell type obtainable in
great quantity from fresh blood. We show that purified
recombinant NadAD351–405 binds to hsp90 in solution and on
the extracellular side of the monocyte plasma membrane were this
heat-shock protein was found to be significantly expressed. We
proved that hsp90, although not the NadAD351–40 receptor, is
nevertheless engaged in the formation of a post-receptor complex
with the purified adhesin, necessary for cell activation and the
following induction of cytokine/chemokine production. Experi-
ment with neutralizing antibodies proved that this process also
involves TLR4.
Results
NadAD351–405 binds to hsp90
Proteins solubilized from human monocytes with TX-100 were
separated by SDS-PAGE, blotted on nitrocellulose and incubated
or not (controls) with purified NadAD351–405. NadA-capturing
bands were detected using rabbit polyclonal antibodies risen
against the whole NadA protein or against the NadA 52–70
sequence and anti-rabbit IgG conjugate to alkaline phosphatase.
As shown in Fig 1, A, both anti-NadA antibodies selectively
stained a polypeptide of ,90 KDa, which was absent in control
samples. Considering the suggested important role of heat shock
protein in microbial factor recognition by immune and epithelial
cells, we tested whether this band had the same mobility of hsp90
in SDS-PAGE. Indeed, specific antibodies to hsp90 but not to the
homologous grp94 stained a polypeptide having the same mobility
of the NadA-interacting protein in a whole monocyte lysates
(Fig. 1, B). Hsp 70, detected with a specific polyclonal antibody,
migrated with a clearly different molecular weight (not shown).
The interaction of NadA with hsp90 was confirmed using purified
human hsp90 as capturing protein in an overlay assay (Fig. 1, C).
Recombinant Hp-Nap, another bacterial virulence factor known
to stimulates monocytes [11], did not bind to purified hsp90 in
overlay assays, suggesting that hsp-90 NadA association is protein-
specific (Fig. 1, C).
In overlay experiments hsp90 folding is significantly lost. Hence,
to determine whether NadA binds also to native hsp90, monocyte
total lysates were incubated in non-denaturating conditions with
NadAD351–405 and with anti-NadA antibodies. The immune
complexes were isolated from the mixture using proteinA
sepharose beads and the co-immune purified proteins were then
analyzed by western blot with specific anti-heat shock proteins
antibodies. Data shows that native hsp90 co-immune isolated with
NadA (Fig. 1, D) while grp94 and hsp70 did not (not shown), in
agreement with overlay data. Electron Spray Mass Spectrometry
after trypsin digestion of NadA co-immune precipitated 90 KDa
band demonstrated definitively that the NadA-binding protein
from monocytes was hsp90 and precisely the most abundant b
isoforms (Fig. 2, Table 1). No significant presence of peptides form
other proteins were detected in correspondence of the eluted 90
KDa band.
Although hsp90 is mostly expressed in the cell cytosol, flow
cytofluorimetry analysis demonstrated that monocytes also display
a significant fraction of this protein on the plasma membrane
(,5% of total cellular amount), in agreement with its proposed
role in the detection of extracellular microbial agonists [12–14]
(Fig. 3, A). Consistently with this information, co-immune
precipitation experiments in which pre-bound NadAD351–405 was
treated with anti-NadA antibodies before detergent monocytes
lysis, showed that hsp90 co-isolated with plasma membrane bound
MenB adhesin (Fig. 3, B).
NadAD351–405 affects the binding of anti-hsp90 antibodies
to hsp90 on monocytes
To collect additional information on recombinant NadA-hsp90
interaction on the monocyte plasma membrane we exploited
specific antibodies to hsp90. Consistent with NadA-hsp90 close
association, we observed that the pre-binding of NadAD351–405 to
cells hampered the subsequent binding of anti-hsp90 antibodies to
hsp90 (Fig. 4 A). This effect progressively occurred at concentra-
tions of soluble adhesin in the micromolar range, in agreement
with the known affinity of NadAD351–405-monocyte binding [9].
Moreover, such a competition only occurred when the recombi-
nant adhesin pre-incubation was performed at physiological
temperature (37uC), a condition required for efficient specific
cell-binding [9] rather than at 0u C. Dose and temperature
dependence both suggest that the interference of anti-hsp90
antibodies to hsp90 correlates with specific NadA cell association.
Similar experiments conducted with anti-hsp70 antibodies
proved that NadAD351–405 cell association also interfered with
their binding to the plasma membrane, where hsp70 was detected
as well (not shown).
Anti-hsp90 antibodies do not affect NadAD351–405
binding to monocytes
The interference of NadAD351–405 with the association of
specific antibodies to hsp90 suggests that they both bind to
hsp90, in agreement with biochemical evidence. This implies that,
if this heat shock protein is the NadA D351–405 receptor or is close
to it, anti-hsp90 antibodies should hamper the binding of the
soluble adhesin to cells. For example, anti-hsp90 antibodies were
found to inhibit the CD14 mediated transfer of LPS to the hsp90/
hsp70/TLR4 signaling multiple complex on human macrophages
[13]. However, pre-treatment of monocytes with anti-hsp90
antibodies to both the COOH an the NH2 terminal domains, or
with a combination of anti-hsp90 and anti-hsp70 antibodies did
not affect whatsoever the binding of NadAD351–405 on human
monocytes at both 0uC and 37uC (Fig 4, B). The lack of a
reciprocal interference effect of NadAD351–405 and anti-hsp90
antibodies with respect to their binding to the monocytes surface
suggests that the interaction with hsp90 is not required for cell
binding of NadAD351–405.
Polymixin B inhibits the interaction of NadAD351–405 with
hsp90 but does not affect its association to monocytes
To gain more information on the possible role of the formation
of the NadAD351–405-hsp90 complex on monocyte, we exploited
polymixin B. We in fact proved that this amphipatic cyclic cationic
Monocytes Activation by NadAD 351-405 Needs Hsp-90
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25089peptide, known to bind to LPS [15], also associates to purified
soluble NadA. Our highly purified, LPS free (,0.05 EU/mg),
NadAD351–405 preparation, was incubated with sepharose-linked
polymixin B in PBS. After extensive washing the presence of the
protein in the matrix was revealed by western blot after SDS-
PAGE separation. As shown in Fig 5, A NadAD351–405 was
prevalently found associated to polymixin B sepharose while not in
solution. Polymixin B inhibited the co-immune isolation of hsp90
from monocyte detergent extracts, but not the binding of anti-
NadA antibody to the adhesin (Fig 5, B). Consistently, the
inhibition of anti-hsp90 antibodies binding to hsp90 on the
monocyte surface by NadAD351–405 was abrogated when polymixin
B was included in the system. All these evidence indicate that
polymixin B binds to NadAD351–405 and blocks its association with
hsp90 (Fig 5, C and D). This notwithstanding, polymixin B did not
affect Alexa-NadA D351–405 binding to monocytes, at either 0uCo r
37uC (Fig 5, E). Data collected with polymixin B are consistent
with those obtained with anti-hsp90 and anti-hsp70 antibodies and
further support that soluble recombinant NadA binds to the
monocyte surface thanks to a receptor different from hsp90 and
interacts only subsequently with hsp90.
Polymixin B blocks NadA D351–405 /dependent cytokine/
chemokine secretion by monocytes
In the previous paragraph we have shown that polymixin B binds
to recombinant NadA,interfering with itsassociation to hsp90 while
not to monocytes. We therefore decided to use polymixin B as a tool
to ascertain the role of hsp90 in monocyte activation induced by
NadAD351–405 [9]. The cytokine/chemokine secretion pattern
induced by NadAD351–405 in monocytes in the presence or not of
polymixin B was analyzed in the extracellular medium. Data (Fig. 6)
show that polymixin B abrogated NadA-induced secretion of
Figure 1. NadAD351–405 binds to human hsp90 in an overlay-assay. A) Samples of total monocytes extracts obtained with 1% TX-100 were
separated by SDS-PAGE and challenged or not as indicated with 1 mM NadAD351–405 after blotting on nitrocellulose. After extensive washings, the
polypeptide bands able to retain NadA were detected with antibodies to the whole adhesin or to NadA 52–70, as indicated. The picture is from a
representative experiment out of four and arrows point to the NadA-interacting ,90 KDa protein. B) Monocytes detergent extracts prepared as in A)
were separated by SDS-PAGE, blotted on nitrocellulose and subjected to western blot with anti- grp94 and hsp90 antibodies or to an overlay assay
with NadA/anti-NadA antibodies. The mobility of the NadA interacting protein and of hsp90 or grp94 was compared. C) Purified human hsp90 were
subjected to overlay assay with (1 mM) or without NadAD351–405 and HP-NAP as indicated. D) Whole TX-100 extracts from human monocytes were
incubated with protein A sepharose-bound anti-NadA IgG in the presence or not of NadAD351–405. After washings, beads were treated with LSB
containing 4%SDS and 10% bme and analyzed by western blot after SDS-PAGE using anti-hsp90 antibodies and alkaline phosphatase-conjugated
anti-IgG secondary antibodies. Arrow points to hsp90, H and L indicate antibody heavy and light chains respectively.
doi:10.1371/journal.pone.0025089.g001
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1b. Polymixin B did not inhibit the cytokine inducing activity of
HpNap on monocytes a bacterial protein acting through TLR2
[11], a fact that excludes a general impairment of cell activation
determined by this substance (not shown).
Binding of anti-hsp90 antibodies to hsp90 on the surface
of monocytes synergizes NadAD351–405 effects in a
polymixin B-insensitive way
We have previously described how antibodies to hsp90 do not
hamper NadAD351–405 binding to monocytes, consistent with the
fact that hsp90 is not the cell receptor for soluble NadA on these
cells. Therefore we also measured the effect of anti-hsp90antibodies
onNadAD351–405-dependent monocyteactivation.Interestingly,co-
incubation of cells with NadAD351–405 and anti-hsp90 antibodies
selectively enhanced TNFa, IL-6, IL-10, IFNc and G-CSF release,
and did not alter MCP-1, IL-17 and IL-8 production (Fig. 7, A).
Moreover, while monocytes cytokine/chemokine secretion induced
byrecombinantNadA alonewastotallyblocked bypolymixinB,the
effects mediated in the presence of anti-hsp90 antibodies were less
or non-sensitive to polymixin B action (Fig. 7, B).
TLR4 is involved in hsp90/NadAD351–405 dependent
monocyte activation
TLR4 has been implicated in the hsp90 mediated activation of
inflammatory cells by LPS and taxol [13]. We hence decided to
Figure 2. Identification of the 90 KDa protein associated with NadA as hsp90 b by MS/MS. The picture shows a typical Coomassie G250
profile of the proteins co-isolated with NadA/anti-NadA immune complexes. The two arrows point to the 90 KDa protein and to 35 KDa NadAD351–405,
while H and L indicate antibody chains. The 90 KDa was excised from the gel for identification by MS/MS sequencing after trypsinization and
identified as the human hsp90 b. The MS full scan (A) and data dependent MS/MS sequencing scans of the high mascot score peptide candidate
764.52 m/z (B) are shown, followed by a table of its Y and B ions (Table 1).
doi:10.1371/journal.pone.0025089.g002
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antibodies on monocyte activation due to NadAD351–405 alone or
in the presence of anti-hsp90 antibodies. We found that only anti-
TLR4 antibodies significantly reduced monocytes cytokine release
in all condition tested, while anti-TLR2 antibodies were without
effects (Fig. 8).
Discussion
It is known that a recombinant and soluble form of the
meningococcal virulence factor NadA (NadAD351–405) not only is a
good immunogen in vivo, but is also a immune-stimulant for
monocytes and monocytes-derived macrophages and dendritic
cells in vitro. Such a self-immune enhancing activity may be
relevant since NadA has been proposed as a vaccine component in
an anti-MenB vaccine formulation. In this work we provide the
first insight on the molecular mechanism underlying the effect of
such soluble recombinant NadA as a specific agonist. We propose
that NadAD351–405 interaction with extracellular, plasma mem-
brane bound, constitutive hsp90 is a requisite for the following
monocyte secretion of cytokines and chemokines. First, we proved
that the recombinant NadA binds to hsp90 in vitro and on the
surface of monocytes, where this heat shock protein, in agreement
with other studies (reviewed in [14]) was detected in significant
amount. Hsp70 was also measured on monocytes but was not
found to bind to NadAD351–405. Mass spectrometry data confirmed
that NadAD351–405 bound to human hsp90 b isoform. On the
contrary Grp94, a membrane heat shock protein belonging to the
hsp90 family and interacting with some bacterial virulence factors
[16], [17], did not interact with NadAD351–405. Indeed, when the
recombinant NadA was pre-bound to monocytes at physiological
temperature (37uC) anti-hsp90 antibodies binding to hsp90 was
inhibited with a dose response compatible with its cell-binding
affinity. This observation again suggests a contact between the
soluble adhesin and hsp90, which inhibits or hinders anti-hsp
antibody association to the same protein. Interestingly, in spite of
no evidence of NadAD351–405/hsp70 association, also anti-hsp70
antibody binding to hsp70 on the surface of monocyte was
hampered by NadA pre-incubation. This observation is consistent
with a close contact between hsp90 and hsp70, and with the
proposed existence of a multiple transducing complex comprising
these two heat shock proteins and other proteins, involved in
activation of inflammatory cells by various microbial agonists. This
competition was on the contrary not observed when NadAD351–405
was pre-bound at 0uC. In a previous study we have shown that
specific association of NadAD351–405 to monocytes was more
efficient at 37uC compared to 0uC. Our data seemed therefore to
suggest hsp90 is the NadA receptor on monocytes. To test this
possibility we studied the effect of anti-hsp90 and anti-hsp70
antibodies pre-incubation on NadA monocyte binding. However,
these antibodies did not inhibit NadAD351–405 binding to
monocytes even when used in combination, at both 0u and
37uC. Our data therefore indicate that NadAD351–405 can associate
to hsp90 on monocytes becoming very close to hsp70 as well,
presumably thanks to lateral diffusion with the already described
hsp90/hsp70 transducing multiple complex [18–20], [13], but that
this is not relevant for cell binding in monocytes, which is
mediated but another still unidentified molecule. Experiments with
Table 1. Peptides identified by the MS/MS tandem analysis.
Start-End m/z Obs Mrexpt Mrcalc Delta Score Sequence
42–53 638.4603 1274.9060 1274.6354 0.2707 60 R.ELISNASDALDK.I
42–53 638.4755 1274.9364 1274.6354 0.3011 21 R.ELISNASDALDK.I
56–64 520.3580 1038.7014 1038.4869 0.2145 48 R.YESLTDPSK.L
73–82 597.9259 1193.8372 1193.6404 0.1968 53 K.IDIIPNPQER.T
83–95 675.5099 1349.0052 1348.7272 0.2781 52 R.TLTLVDTGIGMTK.A
96–107 621.9464 1241.8782 1241.6979 0.1803 67 K.ADLINNLGTIAK.S
187–196 656.3795 1310.7444 1310.5626 0.1818 67 K.EDQTEYLEER.R
205–219 905.1459 1808.2772 1807.9508 0.3264 75 K.HSQFIGYPITLYLEK.E
205–219 603.7777 1808.3113 1807.9508 0.3605 49 K.HSQFIGYPITLYLEK.E
276–284 576.3849 1150.7552 1150.5506 0.2047 42 K.YIDQEELNK.T
285–291 451.3546 900.6946 900.5181 0.1765 30 K.TKPIWTR.N
307–319 764.5203 1527.0260 1526.7365 0.2896 92 K.SLTNDWEDHLAVK.H
307–319 510.0168 1527.0286 1526.7365 0.2921 31 K.SLTNDWEDHLAVK.H
320–330 674.9549 1347.8952 1347.6571 0.2382 57 K.HFSVEGQLEFR.A
331–337 415.3512 827.6878 827.5221 0.1657 42 R.ALLFIPR.R
338–347 618.9285 1235.8424 1235.6298 0.2126 32 R.RAPFDLFENK.K
360–378 1187.8018 2373.5890 2373.1384 0.4506 54 R.VFIMDSCDELIPEYLNFIR.G
360–378 792.2254 2373.6544 2373.1384 0.5159 21 R.VFIMDSCDELIPEYLNFIR.G
379–392 757.5038 1512.9930 1512.7783 0.2147 77 R.GVVDSEDLPLNISR.E
539–550 708.9680 1415.9214 1415.6303 0.2911 58 K.EGLELPEDEEEK.K
Peptides identified by the MS/MS analysis and recognized by Mascot. In the columns are indicated, from left to right: the relative sequence position; the experimental
m/z value (m/z Obs); the theoretical molecular weight, in Dalton, obtained from the Swiss-Prot and ExPASy databases (Mrexp); the relative molecular mass calculated
from the matched peptide (Mrcalc); the difference between the experimental and calculated masses (Delta); the Mascot score for the identified protein (Score) and the
sequence of the peptide. The peptide with the highest score is highlighted in bold and used as example of MS/MS scan analysis in Fig. 2. All shown peptides belong to
human hsp90 b.
doi:10.1371/journal.pone.0025089.t001
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to bind to NadAD351–405 and, as a result, to interfere with the
formation of the NadA/hsp90 in solution and the surface of
monocytes, but was again without any effect on the extent of
recombinant NadA-monocyte binding at 0uC and 37uC.
In the second part of our manuscript we focused on the
possibility that the formation of the NadAD351–405 -hsp90 complex,
although not necessary for cell binding, is nevertheless necessary
for cell activation. In fact NadA is well known to stimulate
monocytes [9]. To address this issue we used polymixin B and
anti-hsp90 antibodies.
We found that polymixin B efficiently blocks cytokine/
chemokine secretion induced by NadAD351–405, indicating that
binding to monocytes without the subsequent engagement of
hsp90 is not sufficient to stimulate cells.
Surprisingly, we found that co-incubation of NadAD351–405 with
anti-hsp90 antibodies synergized the effects of the men B adhesin
in a selective way increasing the secretion of most, although not all,
cytokines/chemokines. In addition, cell activation due to the
presence of both agonists was much less or not at all sensitive to
the presence of polymixin B. We conclude that binding of anti-
hsp90 antibodies to hsp90 can vicariate the need for NadAD351–405
interaction with the same protein. Since hsp90 was not strongly
stimulatory per se, at least at these concentrations, this implies that
NadAD351–405 cell association to sites other to hsp90 insensitive to
polymixin B, is necessary, although not sufficient, for monocyte
stimulation. It remains that, in physiological conditions hsp90
involvement appears necessary for the immune effects induced by
recombinant NadA. Finally, using specific anti-TLRs neutralizing
antibodies, we showed that cytokine/chemokine induction by
NadAD351–405 requires the transmembrane signaling operated by
TLR4, but not by TLR2.
One aspect of our data deserves a special consideration: the
analogy between NadAD351–405 and LPS effects. Both agonists
induce cytokines/chemokines by monocytes in a polymixin B
sensitive and TLR4 dependent way. This may indicate that a small
amount of LPS below the detection limit of our assay is indeed
complexed with NadAD351–405 and is responsible for its interaction
with polymixin B and for its biological effects on monocytes.
However, we have already proved in our previous work that
NadAD351–405 effect on monocytes is temperature sensitive and
that its quantitative elimination from the solution by immune
precipitation with specific antibodies abolishes such activity [9].
Moreover, in this manuscript we showed that while NadAD351–405-
induced cytokine production was polymixin B sensitive the
enhanced action of NadA plus anti-hsp90 antibodies was not.
Finally, biochemical evidence show that all NadAD351–405 trimers
bind to a polymixin B matrix in solution so implying that LPS, to
account for such binding, should be complexed with the protein in
an equimolar ratio and therefore present in detectable amount in
our preparations. For all these arguments we believe that indirect
evidence make the possibility that LPS is the real actor of pro-
inflammatory effect displayed by NadAD351–405 preparation very
unlikely.
Fig. 9 details the model of monocyte activation by the
recombinant NadA we propose. According to our view, the men
B adhesin soluble form binds to a till unknown plasma membrane
receptor and then, presumably by lateral diffusion, it encounters
hsp90 and is recruited into a complex also comprising hsp70 and
TLR4. Such association, necessary for full cell stimulation is
Figure 3. Hsp90 is present on the surface of human monocytes and co-immune isolates with plasma membrane-bound NadA. A)
Cells were pre-saturated with human serum to block non-specific antibody binding and then treated with anti-hsp90 and PE-conjugated anti-IgG
antibodies for 2 hours at 0uC. Mean fluorescence intensity was quantified by flow-cytofluorimetry. Data are the mean of three experiments run in
duplicate and bars represent +/2 SE. B) Monocytes were pre-treated or not with NadAD351–405 (5 mM) for 3 hours at 37uC, washed with PBS at 0uC and
further incubated with anti-NadA antibodies (1 mg/ml) at the same temperature. After three hours, cells were washed again, dissolved with 1% TX-
100 and protein recovered by protein A-sepharose beads were subjected to western blot with specific anti-antibodies to reveal hsp90 (pointed by an
arrow).
doi:10.1371/journal.pone.0025089.g003
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hsp90 interaction but not with NadAD351–405 cell binding. Co-
stimulation with anti-hsp90 antibodies not only abolishes poly-
mixin B sensitivity of NadAD351–405 effects, i.e. the need for
NadAD351–405/hsp90 association, but, paradoxically, optimizes the
production of cytokines/chemokines. Our data are reminiscent of
the proposed model of LPS-LTA activation of inflammatory cells
proposed by [13]. These authors demonstrated that a complex
formed by hsp90/hsp70/TLR4/TLR2, and possibly other
components, accepts endotoxin after its binding to the plasma
membrane LPS co-receptor CD14. In that case however,
saturation with anti-hsp90/hsp70 antibody impeded LPS binding
and stimulation to the transducing system. On the contrary, we
here propose that engagement of hsp90 with specific antibodies
mimics the interaction of the adhesin itself with the same
protein, which occurs in physiological conditions. In the case of
NadAD351–405, hsp90/TLR4 involvement, although not sufficient
to stimulate cells per se, generates a synergy with the effects
mediated by the NadA/NadA receptor complex able to stimulate
monocytes. In conclusion, our data show that surface-bound hsp90
is a central player in the immune-modulatory effects mediated by
the soluble form of NadA selected as a vaccine candidate against
N. meningitidis B.
Our data indicates that targeting of surface hsp90 may be
important to modulate or enhance the efficacy of vaccines or to
induce an adjuvant effect, consistent with a general role of hsp90
as an innate immune regulator. On the other hand, since NadA
expressing model bacteria or OMVs also show enhanced pro-
immune/pro-inflammatory activity compared to negative strains
or to NadA lacking OMVs [9,10] our data allows the hypothesis
that the interaction with hsp90 can take place also in the case of
native-full-length NadA and may be relevant in the cell interaction
of NadA + N. meningitidis cells during infection.
Materials and Methods
Ethics Statement
Peripheral blood mononuclear cells utilized in this study derived
from buffy coats obtained from healthy blood donors, as
anonymously provided by the Transfusional Center of the
Hospital of Padova. Written informed consent for the use of buffy
coats for research purposes was obtained from blood donors by
Transfusional Center. Data related to human samples were all
analyzed anonymously. Human leukocytes were obtained not
consequently to experimentation on human beings but as a
consequence of voluntary and informed blood donation for
transfusions: no approval of Ethics Committee is needed in such
cases in our institution.
This study was conducted according to European Union
guidelines for the handling of laboratory animals (86/609 CEE
normative, Italian legislative act 116/92). Immunization protocol
for antibody production in rabbits (purchased from Harlan
Laboratories company) were approved by the Veterinary Service
of the University of Padova (project name: Immunoglobulin
generation against specific regions of prokaryotic and/or eukary-
otic proteins in rabbits – notified to the Italian Health Ministry on
13th October 2006- responsible prof. Emanuele Papini). The
Italian legislation for experiments of antibodies production like the
ones performed in rabbits in our work foresees the rule of silence/
assent with the Minister (Decreto Legislativo 116/92). Moreover
at the time 2006–2009 the ethical committee for animal
experimentation, which can be activated on a voluntary base by
Italian universities according to the legislation, was not present yet
in our university. For this reason we have no protocol number ID
or any formal approval.
NadA and labeling of NadAD351–405 to Alexa
Soluble recombinant NadA was designed as previously described
and purified to clinical trial standard [3]. In brief, the DNA
sequence of nadA allele 3, cloned from the hypervirulent
N. meningitidis B strain 2996, encoding the deletion mutant
NadAD351–405, with no outer membrane anchor, was cloned into
a pET21b vector (Novagen). The protein secreted in the
extracellular medium of the transformed Escherichia coli BL21(DE3)-
NadAD351–405 strain was purified by Q Sepharose XL, Phenyl
Figure 4. Analysis of the reciprocal interference of NadAD351–405
and anti-hsp90 antibodies to the monocyte surface at 376 and
06C. A) Human monocytes were incubated for 1 hours at 0uC in RPMI,
10% FCS, containing NadAD351–405 at the indicated concentrations. After
washing at 0uC cells were further incubated with anti-hsp90 antibody
and anti-IgG PE-labeled secondary antibodies. MFI was then analyzed
by flow-cytofluorimetry. Data are from an experiment representative of
four, and bars represent +/2 SE. Asterisk indicates signals significantly
different (p,0.05) from control (0uC). B) Monocytes were pre-treated or
not with anti-hsp90 antibodies (40 mg/ml) for 1 hour at 0uC, washed as
above and further incubated at the indicated temperature with Alexa-
labeled NadAD351–405. Graphs are made with mean values from a
representative experiment of four. Bars are +/2 SE.
doi:10.1371/journal.pone.0025089.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25089Figure 5. Polymixin B binds to NadAD351–405, inhibits the formation of the NadAD351–405/hsp90 complex but does not hamper
NadAD351–405 monocyte binding. A) 0.1 ml of NadAD351–405 solution in PBS (10 mg/ml) was incubated with polymixin B agarose at room
temperature for 2 hours. Beads were recovered by centrifugation, and corresponding supernatant and pellets, washed in PBS, were subjected to SDS-
PAGE to reveal NadA presence by Coomassie staining (arrow). A reference lane containing 1 mg NadAD351–405 was run in parallel. B) Monocyte
detergent extracts were subjected to co-immune isolation with proteinA-sepharose bound anti-NadA antibodies and NadAD351–405 plus or minus
10 mg/ml polymixin B, as indicated. Proteins were separated by SDS-PAGE and silver stained. The arrows points to hsp90 or to NadA; H and L indicate
the chains of anti-NadA antibodies. C, D) Monocytes were incubated with the indicated concentrations of NadAD351–405 at 0u C (C) or 37uC (D) in the
presence (black circles) or in the absence (open circles) of 20 mg/ml polymixin B for three hours in culture medium. After washings with PBS, at 0uC,
cells were further incubated with anti-hsp90 antibodies and with PE-conjugated secondary antibodies. Cell fluorescence (MFI), quantified by flow-
cytofluorimetry, corresponds to the mean of three experiments run in triplicate and bars represent +/2 S.E. Asterisk indicates signals significantly
different (p,0.05) from control (no adhesin present in the system). E) Monocytes were incubated with 600 nM Alexa NadAD351–405 at 0uCo r3 7 uCi n
the presence of increasing concentrations of polymixin B. Cells were washed and treated at 4uC with anti-hsp90 and anti-IgG PE-conjugated
antibodies keeping polymixin B in the solutions where necessary. Cell fluorescence (MFI), quantified by flow-cytofluorimetry, corresponds to the
mean of three experiments run in triplicate and bars represent +/2 S.E.
doi:10.1371/journal.pone.0025089.g005
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column (HA Macro-Prep, BioRad) chromatographies. Preparations
of purified NadAD351–405 showed a single 35 KDa band after SDS-
PAGE and silver staining, consistent with the predicted molecular
weight., and is a homotrimer, as assessed by light scattering analysis
[5]. Reverse-phase separation of NadAD351–405 preparation in
denaturating conditions showed a single peak homogeneously
corresponding to the 1–315 sequence of mature NadA protein, as
determined by MALDI-TOFF mass spectrometry analysis. LPS
contamination (tested by Limulus test kit from Sigma-Aldrich) was
,0.005 EU/mg of protein. Bacterial DNA contamination (deter-
mined by an enzymatic assay) was 0.6–0.7 pg/mg of protein. No E.
coliAgsweredetected byWesternimmunoblotanalysiswitha rabbit
polyclonal Ab risen against whole E. coli cells (DakoCytomation).
Aliquots of protein solution (2 mg/ml in PBS, pH 7.4) were frozen
in liquid nitrogen and stored at –80uC. NadAD351–405 concentration
was expressed based on the monomer molecular weight.
NadAD351–405 was conjugated to the fluorescent probe Alexa
488 using a N-hydroxysuccinimidyl derivative (Molecular Probes)
according to the manufacturer’s instructions. Alexa- NadAD351–405
was separated from left reagents by size exclusion chromatography
using Sephadex G25 (Sigma-Aldrich) columns pre-equilibrated
and eluted with PBS at room temperature.
Antibodies
Rabbit anti-hsp90(H114), against peptide 610–723 of C-terminal
human hsp90, goat anti-hsp90(N17), against N-terminal region of
human hsp90, and goat anti-hsp70(K20), against a C-terminal
peptide ofhuman hsp70,antibodies (Abs)wereobtained from Santa
Cruz Biotechnology. Anti-human TLR4 and anti-human TLR2
monoclonal Abs were obtained from eBioscence (USA). Secondary
Abs (goat anti-rabbit AP- or PE conjugated, mouse anti-goat PA- or
FITC conjugated) were from Molecolar Probes.
Generation and purification of rabbit polyclonal anti-
NadAD351–405 and anti-NadA peptides Abs
Polyclonal antiserum against NadAD351–405 or 52–70 NadA
peptide were generated by immunizing male white rabbits (Harlan
Laboratories) with 50 mg of whole protein or 2 mg purified peptide
conjugated with 2 mg of keyhole limpet hemocyanin (KLH,
Pierce): soluble NadA or a fourth of peptide-KLH complex were
homogenized with complete Freund’s adjuvant (Sigma) and used
to immunize rabbits by cutaneous injection. Three boosters (50 mg
of NadA and an aliquot of peptide, homogenized with incomplete
Freund’s adjuvant- Sigma) were given at days 18, 34, and 52 by
intramuscular injection. Antiserum was harvested on day 68 and
stored at 220uC.
NadAD351–405 Abs were obtained using Protein A-Sepharose
beads (Pharmacia Biotech); 52–70 NadA peptides Abs were
purified using an affinity chromatography, prepared with 52–70
NadA peptide covalent bound to sulfolink coupling gel (Pierce).
Ligand overlay assay
Cells (10
6) were solubilized in 100 ml lysis buffer (1% v/v Triton
X-100 in PBS) containing a mix of protease inhibitors (Roche
diagnostic) for 30 min at 4uC. Lysates were then centrifuged for
5 min at 15.000g to separate cell debris and nuclei. Samples were
mixed with Laemmli sample buffer (LSB) and boiled for 5 min at
95uC. Proteins were fractionated on 12% SDS-polyacrylamide gel,
blotted onto nitrocellulose membrane and blocked in TBS (50mM
Tris-HCl, pH7.5, 100 mM NaCl) –0.1% Tween 20 containing 1%
BSA (blocking buffer) at room temperature for 2h. Blots were then
incubated in blocking buffer containing or not 1 mM NadAD351–405
for 8h at 4uC under gently shaking. After 3 washings in TBS–0.1%
Tween 20,blots were incubatedwith anti-NadAD351–405, anti-NadA
peptides, anti-hsp90 or anti-grp94 Abs, and then with secondary
PA-conjugated Abs. Bound proteins were detected with NBT-BCIP
solutions (Sigma).
Co-immunoprecipitation
10610
6 cells were solubilized in 1 ml lysis buffer containing
protease inhibitors at 4uC for 30 min and then lysates were
centrifuged for 5 min at 15.000g. Supernatants were then incubated
with Protein A-Sepharose, previously bound to anti-NadAD351–405
antibodies and NadAD351–405; co-immunoprecipitation was per-
formed for 2 hours at 4uC. In some experiments, co-immunopre-
cipitation was performed in the presence of 10 mg/ml polymixin B.
Alternatively, monocytes were incubated for 3 h at 37uC with 5 mM
Figure 6. Polymixin B inhibits the induction of cytokine/chemokine by NadAD351–405 in monocytes. Human monocytes were stimulated
for 24 hours with the indicated concentrations of NadAD351–405 in the absence (open circles) or in the presence of 10 mg/ml polymixin B in DMEM plus
10% FCS. Cytokines/chemokines were subsequently quantified in the cells extracellular medium using a BioPlex assay. Data are from a representative
experiment of three, run in duplicate and bars are ranges.
doi:10.1371/journal.pone.0025089.g006
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then with anti-NadAD351–405 Abs (1 mg/ml) for 3 hours. Cells were
scraped and lysed and incubated with Protein A-sepharose beads.
After 2 hours incubation, beads were washed, resuspended in LSB
and analyzed by western blotting or protein staining.
In-Gel Digestion, MS/MS protein identification and
database search
Excised from the gel, spot was washed with 50% v/v acetonitrile
(ACN) in 0.1 M NH4HCO3, and vacuum-dried. The gel
fragments were reduced for 45 min at 55uC in 10 mM DTT in
0.1 M NH4HCO3. After cooling, the DTT solution was
immediately replaced with 55 mM iodoacetamide in 0.1 M
NH4HCO3. After washing with 50% ACN in 0.1 M NH4HCO3,
the dried gel pieces were swollen in a minimum volume of 10 ml
digestion buffer containing 25 mM NH4HCO3 and 12.5 ng/l
trypsin (Promega) and incubated overnight at 37uC. Tryptic-
digested peptides were extracted according to the protocol
described by Bozzo et al. [21].
Protein digestion was performed according to Shevchenko et al.
[22] with minor modifications. The dried tryptic digest samples were
reconstituted in 10 ml of 0.5% TFA in water and were purified with a
ZipTipC18 (Millipore). For electrospray MS analysis, the peptides
were eluted in 50% acetonitrile containing 0.2% formic acid. Data
were collected on a Micromass Q-Tof Micro mass spectrometer
(Manchester, UK) (capillary voltage: 3000–3200 V; cone voltage:
45 V; scan time: 1 s; interscan: 0.1 s). Spectra were analyzed using
Micromass MassLynx V4.1 software. The MASCOT program
(Matrix Science, www.matrix-science.com) was used to search for all
MS/MS spectra against the Swiss-Prot database. The following
parameters were used in the MASCOT search: trypsin specificity;
maximum number of missed cleavages: 1; fixed modification:
carbamidomethyl (Cys); variable modifications: oxidation (Met);
peptide mass tolerance: 61.0 Da; fragment mass tolerance: 60.5
Da; protein mass: unrestricted; mass values: monoisotopic.
Cell culture
Monocytes were obtained from buffy coats from healthy donors.
Leukocyte-enriched plasma was centrifuged over Ficoll-Hypaque
(Amersham Biosciences) and Percoll (Amersham Pharmacia
Biotech). Mononuclear cells were washed, resuspended in RPMI
medium (Gibco) supplemented with 2% fetal calf serum, 50 mg/ml
gentamicin, and plated onto a 24-well plate (Falcon). After 1 h-
incubation at 37uC in a 5% CO2 atmosphere, non adherent cells
were removed. The purity of preparations (percentage of CD14-
positive cells) and cell viability (using the Trypan blue exclusion test)
were higher than 98%. All cells were kept at 37uC in a humidified
atmosphere containing 5% (v/v) CO2 unless otherwise specified.
Binding of NadAD351–405 to polymyxin B
3610
5 cells were solubilized in 1 ml lysis buffer containing
protease inhibitors at 4uC for 30 min; lysates were then
centrifuged for 5 min at 15000g. 200 ml of polymyxin B-agarose
resin (Sigma-Aldrich) for each sample were incubated 1 h at room
temperature under gently shacking with NadAD351–405 or with
lysates. After 2 washing in PBS the supernatant and the resin were
mixed with LSB, 5% b-mercaptoethanol and boiled for 5 min at
95uC. Proteins were fractionated on 12% SDS-polyacrylamide gel
and Coomassie stained.
Flow cytometry analysis of hsp90 expression
To quantify hsp90 expression on the surface of monocytes,
5610
5 cells were treated for 30 min at 37uC with human serum, to
block the Fc receptor expressed on the surface of monocytes, and
then for 1h at 4uC with 10 mg/ml of anti-hsp90 Ab. After washing,
cells were incubated for 1h at 4uC with 10 mg/ml of PE-
conjugated Ab. Total amount of hsp90 was measured in the same
way after cells permeabilization, performed by treating cells
Figure 7. Anti-hsp90 antibodies increase NadAD351–405 monocyte stimulation in a polymixin B insensitive-way. A) Cells were treated
with NadAD351–405 in the absence (black circles) or in the presence (open circles) of purified rabbit polyclonal antibodies directed to the COOH
terminal domain of hsp90. Open squares refers to cells incubated with NadAD351–405 in the presence of purified rabbit polyclonal antibodies from non
immunized animals. The indicated cytokines/chemokines were analyzed in the extracellular medium by BioPlex suspension arrays. Data are the mean
from a representative experiment out of four run in triplicate. Bars are +/2 SE. Asterisk indicates signals significantly different (p,0.05) from control
(with or without an unrelated antibody). B) Monocytes were stimulated or not with NadAD351–405 (1.5 mM) as indicated, in the presence of polymixin B
(black bars), antibodies to the COOH terminal of hsp90 (hatched bats) and in the presence of both polymixin B and anti-hsp90 antibodies (light gray
bars). After 1 hour incubation, the indicated cytokines/chemokines were analyzed in the extracellular medium as indicated above. Data are the mean
of two experiments run in triplicate. Bars represent +/2 SE.
doi:10.1371/journal.pone.0025089.g007
Figure 8. Effect of neutralizing anti-TLR4 and anti-TLR2
antibodies on NadAD351–405 and NadAD351–405/anti-hsp90 in-
duced monocyte activation. Cells were incubated with NadA or with
NadA and anti-hsp90 antibodies, after pre-treatment with neutralising
antibodies to TLR4 or TLR2, as indicated. After 24 hours, the content of
the three indicated cytokines was measured in the extracellular medium
with a Bio-Plex suspension array. Data are expressed as percentage of
the effect induced by adhesin or adhesin plus anti-hsp90 antibodies
effects, in the absence of anti-TLR antibodies, and are the mean of three
independent experiments run in triplicate +/2 SE.
doi:10.1371/journal.pone.0025089.g008
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at 4uC in methanol.
In some experiments, monocytes were pre-incubated for 3h at 4
or 37uC with different concentrations of NadAD351–405 (from 0.6 to
5 mM), in the presence or in the absence of 10 mg/ml polymyxin
B, in RPMI-1640, 10% FCS, 50 mg/ml gentamicin. After three
washings in PBS, monocytes were incubated 1h at 4uC with
10 mg/ml anti-hsp90(H114), anti-hsp90(N17) and anti-hsp70(K20)
Abs in PBS. Cells were subsequently washed and then treated 1h
at 4uC with the appropriated secondary Abs.
After the specific treatments, cells were washed, re-suspended in
PBS/1% FCS and analyzed on a FACS Calibur
TM flow cytometer
(BD Bioscience), adding propidium iodide to eliminate dead cells.
Data were collected on 10000–20000 events.
Bioplex multiplex cytokine assay
Human adherent monocytes were incubated for 24 h in RPMI
plus 10% FCS, 50 mg/ml gentamicin, with or without different
concentration of NadAD351–405 (from 0.6 to 3 mM), or/and 10 mg/
ml anti-hsp90 (N and C terminal) Abs, or/and 10 mg/ml anti-
hsp70 Abs, or/and 10 mg/ml anti-TLR2 or anti-TLR4 Abs, or/
and 10 mg/ml polymixin B, and then culture supernatants were
collected for performing the assay. A Procarta 22- or 3- cytokines
assay kit (Panomix) was used and the assay was performed
according to the manufacturer’s instructions. Calibration curves
from recombinant cytokine standards were prepared with four-
fold dilution steps in RPMI-1640 medium containing 10% FBS,
50 mg/ml gentamicin. All assays were carried out in 96-well sterile,
prewetted filter plates at room temperature and protected from
light. A mixture containing 5000 microspheres per cytokine was
incubated together with standards or samples in a final volume of
100 ml for 30 min under continuous shaking (300 rpm). After
three washes by vacuum filtration with the washing buffer, a
cocktail of biotinylated antibodies diluted in the detection antibody
diluent was added. After 30 min incubation and washing,
Streptavidin-PE diluted in the assay buffer was added. At the
end of 30 min incubation, under continuous shaking and after
washing, the fluorescence intensity of the beads was measured in a
final volume of 120 ml of the assay buffer. Data analysis was done
with Bio-Plex Manager software using a five-parametric curve-
fitting. The detection limit of the assay for all antigens was 1 pg/
ml.
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